EMEA-002255-PIP01-17
Key facts
| Active substance |
polatuzumab vedotin
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0117/2018
|
| PIP number |
EMEA-002255-PIP01-17
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Roche Registration Limited
Tel. +41 616879411
E-mail: global.paediatrics@roche.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions/indications
|